Elabela在心血管疾病中的作用研究进展

    Research progress on the role of Elabela in cardiovascular diseases

    • 摘要: Elabela(也称为Apela、Ende和Toddler)是一种小信号肽,可激活G蛋白耦联受体Aplnr,是一种与心脏发育相关的肽类激素,与Apelin具有共同的G蛋白耦联受体(apelin peptide jejunum,APJ),Elabela被认为是心血管稳态的重要调节剂,可能成为多种心血管疾病(cardiovascular disease,CVD)的新型治疗靶点。生理水平的Elabela具有促进血管生成和血管舒张作用,对心脏发育起到至关重要的作用。病理水平的Elabela可能是各种 CVD 的新型诊断生物标志物。机体外周静脉应用Elabela后可具有“抗高血压、血管保护和心脏保护”作用,Elabela是CVD的关键治疗和诊断靶点,对于心肌梗死、缺血再灌注损伤、心力衰竭、动脉粥样硬化、高血压等具有显著的治疗作用。本综述旨在描述Elabela在心血管疾病中的生理和病理作用。

       

      Abstract: Elabela (also known as Apela, Ende, and Toddler) is a small signal peptide that activates the G protein coupled receptor Aplnr. It is a peptide hormone related to heart development and shares the same G protein coupled receptor (APJ) with Apelin. Elabela is considered an important regulator of cardiovascular homeostasis and may become a new therapeutic target for various cardiovascular diseases (CVD). At the physiological level, Elabela has angiogenesis and vasodilation effects, playing a crucial role in heart development. Elabela at the pathological level may be a novel diagnostic biomarker for various CVD. Elabela can have the effect of "anti hypertension, vascular protection and heart protection" after being used in the peripheral vein of the body. Elabela is the key treatment and diagnostic target of CVD, and has significant therapeutic effect on myocardial infarction, ischemia reperfusion injury, heart failure, atherosclerosis, hypertension, etc. This review aims to describe the physiological and pathological roles of Elabela in cardiovascular diseases.

       

    /

    返回文章
    返回